The BLOODSAFE program: Building the future of access to safe blood in Sub-Saharan Africa.
Sub-Saharan Africa
blood donation
blood transfusion
implementation science
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
revised:
30
06
2022
received:
15
05
2022
accepted:
12
07
2022
pubmed:
30
9
2022
medline:
10
11
2022
entrez:
29
9
2022
Statut:
ppublish
Résumé
The supply of blood in many low- and middle-income nations in Sub-Saharan Africa (SSA) does not meet the patient care needs. Lack and delay of blood transfusion cause harm to patients and slow the rate of progress in other parts of the health system. Recognizing the power of implementation science, the BLOODSAFE Program was initiated which supports three SSA research study teams and one data coordinating center (DCC) with the goal to improve access to safe blood transfusion in SSA. The study team in Ghana is focusing on studying and decreasing iron deficiency in blood donors and evaluating social engagement of blood donors through different approaches. The study team in Kenya is building a "vein to vein" workflow model to elucidate and devise strategies to overcome barriers to blood donation and improve infrastructural components of blood product production and use. The Malawi team is studying the infectious disease ramifications of blood donation as well as blood donor retention strategies aimed at blood donors who commence their donation career in secondary schools. Together the project teams and the DCC work as a consortium to support each other through a shared study protocol that will study donor motivations, outcomes, and adverse events across all three countries. The BLOODSAFE Program has the potential to lead to generalizable improvement approaches for increasing access to safe blood in SSA as well as mentoring and building the research capacity and careers of many investigators.
Sections du résumé
BACKGROUND
The supply of blood in many low- and middle-income nations in Sub-Saharan Africa (SSA) does not meet the patient care needs. Lack and delay of blood transfusion cause harm to patients and slow the rate of progress in other parts of the health system. Recognizing the power of implementation science, the BLOODSAFE Program was initiated which supports three SSA research study teams and one data coordinating center (DCC) with the goal to improve access to safe blood transfusion in SSA.
STUDY DESIGN AND METHODS
The study team in Ghana is focusing on studying and decreasing iron deficiency in blood donors and evaluating social engagement of blood donors through different approaches. The study team in Kenya is building a "vein to vein" workflow model to elucidate and devise strategies to overcome barriers to blood donation and improve infrastructural components of blood product production and use. The Malawi team is studying the infectious disease ramifications of blood donation as well as blood donor retention strategies aimed at blood donors who commence their donation career in secondary schools.
RESULTS AND DISCUSSION
Together the project teams and the DCC work as a consortium to support each other through a shared study protocol that will study donor motivations, outcomes, and adverse events across all three countries. The BLOODSAFE Program has the potential to lead to generalizable improvement approaches for increasing access to safe blood in SSA as well as mentoring and building the research capacity and careers of many investigators.
Identifiants
pubmed: 36173295
doi: 10.1111/trf.17091
pmc: PMC9643608
mid: NIHMS1835594
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2282-2290Subventions
Organisme : NHLBI NIH HHS
ID : UG3HL151595
Pays : United States
Organisme : NHLBI NIH HHS
ID : UH3 HL151595
Pays : United States
Organisme : NHLBI NIH HHS
ID : U24 HL151541
Pays : United States
Organisme : NHLBI NIH HHS
ID : UG3 HL152189
Pays : United States
Organisme : NIGMS NIH HHS
ID : K23 GM141463
Pays : United States
Organisme : NHLBI NIH HHS
ID : UG3 HL151595
Pays : United States
Organisme : NHLBI NIH HHS
ID : UG3 HL151599
Pays : United States
Organisme : NHLBI NIH HHS
ID : U24HL151541
Pays : United States
Organisme : NHLBI NIH HHS
ID : UH3 HL151599
Pays : United States
Organisme : NHLBI NIH HHS
ID : UG3HL151599
Pays : United States
Organisme : NHLBI NIH HHS
ID : UG3HL152189
Pays : United States
Informations de copyright
© 2022 AABB.
Références
SAGE Open Med. 2021 Nov 10;9:20503121211054995
pubmed: 34790356
Lancet. 2018 Nov 10;392(10159):1684-1735
pubmed: 30496102
Malawi Med J. 2019 Jun;31(2):118-125
pubmed: 31452844
Lancet. 2018 Nov 17;392(10160):2214-2228
pubmed: 30314860
Br J Haematol. 2017 Jun;177(6):864-877
pubmed: 28542841
Malawi Med J. 2017 Jun;29(2):194-197
pubmed: 28955432
Lancet Haematol. 2021 Oct;8(10):e770-e776
pubmed: 34481544
J Ayub Med Coll Abbottabad. 2002 Apr-Jun;14(2):24-7
pubmed: 12238342
Lancet. 2007 Aug 11;370(9586):511-20
pubmed: 17693180
Transfus Med Rev. 2015 Jul;29(3):195-204
pubmed: 25752939
Transfusion. 2018 May;58(5):1307-1317
pubmed: 29542130
Transfus Med Rev. 2012 Jul;26(3):224-237.e6
pubmed: 22126711
Lancet. 2016 Jan 30;387(10017):462-74
pubmed: 26584737
Hematol Oncol Clin North Am. 2016 Apr;30(2):477-95
pubmed: 27040966
Vox Sang. 2021 Aug;116(7):774-784
pubmed: 33529421
Lancet Haematol. 2019 Dec;6(12):e606-e615
pubmed: 31631023
BJOG. 2014 Sep;121 Suppl 4:95-101
pubmed: 25236641
Blood. 2014 Jan 30;123(5):615-24
pubmed: 24297872
Blood Transfus. 2014 Jan;12 Suppl 1:s37-43
pubmed: 23522891